SEC Comment Letter 0000000000-23-003544 to AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc.
Date: April 10, 2023 · CIK: 0001880438 · Accession: 0000000000-23-003544
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271174
Letter
United States securities and exchange commission logo April 10, 2023 Eric Easom President and Chief Executive Officer AN2 Therapeutics, Inc. 1800 El Camino Real, Suite D Menlo Park, CA 94027 Re:AN2 Therapeutics, Inc. Registration Statement on Form S-3 Filed April 6, 2023 File No. 333-271174 Dear Eric Easom: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Anitha Anne
Show Raw Text
United States securities and exchange commission logo
April 10, 2023
Eric Easom
President and Chief Executive Officer
AN2 Therapeutics, Inc.
1800 El Camino Real, Suite D
Menlo Park, CA 94027
Re:AN2 Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 6, 2023
File No. 333-271174
Dear Eric Easom:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Anitha Anne